NCT06971224 NADream: Effects of Nicotinamide Adenine Dinucleotide Supplementation on Sleep Quality in Healthy Individuals

Trial Parameters

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The purpose of this study is to evalue the effects of nicotinamide adenine dinucleotide (NAD) supplementation (nicotinamide riboside (NR) form) on sleep in healthy adults compared to a placebo. NAD is important for brain health and energy balance and a proposed explanation for its effect on sleep is that NAD supplementation restores the neurophysiological capacity of the brain to 'rest' during sleep. If this is the case, we expect the administration to result in improvements in sleep quality (and most likely sleep quantity) compared to placebo. Participants will receive either NAD supplementation or a placebo and their sleep will be measured to detect any differences between the two groups.

Eligibility Criteria

Inclusion Criteria: * Participant must be 40 to 60 years of age inclusive, at the time of signing the informed consent. * Male or female. * Participants who are healthy as determined by medical evaluation including medical history and physical examination. * Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the study protocol. * Self-reported normal sleep patterns, assessed by Pittsburgh sleep quality index (PSQI; cutoff ≤ 5). * No current use of sleep medications or supplements. * Able to wear polysomnographic equipment and actigraphy during nighttime. Exclusion Criteria: * History of sleep disorders (e.g. insomnia, sleep apnea). * Abnormal findings on PSG, such as sleep related breathing disorders (apnea-hypopnea index (AHI) ≥ 5), sleep related movement disorders (periodic limb movement index (PLMI) ≥ 15, and parasomnias (like REM sleep behavior disorder (RBD)). * Chronic use of alcohol, tobacco, or medications affect

Related Trials